The Wait Is Over — FDA Approves Device for Long-Standing Persistent Afib

We could practically hear it in AtriCure CEO Mike Carrel's voice on Tuesday, as analysts pressed him for an update regarding the company's EPi-Sense device for atrial fibrillation (Afib). Carrel knew what everyone on the first-quarter earnings call were chomping at the bit to hear, but without having "paper in hand," as he said, he had no choice but to keep it close to the vest.